Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer's disease
Sha Sha
Lina Ren
Xiaona Xing
Wanshu Guo
Yan Wang
Ying Li
Yunpeng Cao
Le Qu
Abstract：Alzheimer's disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer's disease. Conventional drugs, such as donepezil, can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline. Currently, active and passive immunotherapies targeting amyloid-beta and tau have shown some efficacy in mice with asymptomatic Alzheimer's disease and other transgenic animal models, attracting considerable attention. However, the clinical application of these immunotherapies demonstrated only limited efficacy before the discovery of lecanemab and donanemab. This review first discusses the advancements in the pathogenesis of Alzheimer's disease and active and passive immunotherapies targeting amyloid-beta and tau proteins. Furthermore, it reviews the advantages and disadvantages of various immunotherapies and considers their future prospects. Although some antibodies have shown promise in patients with mild Alzheimer's disease, substantial clinical data are still lacking to validate their effectiveness in individuals with moderate Alzheimer's disease.
Keywords：Alzheimer's diseaseamyloid depositsamyloid-betaantibodycognitive dysfunctiondementiaimmunotherapyoligomerpreventive immunizationtau hyperphosphorylation
Publication Date：2026-02-28
Online Publishing Date：2025-12-09(First online date of this platform, not the publication date of the document)
Pages：11( 577-587 )